IGC Pharma (IGC) investor relations material

Executive summary

• Clinical-stage company focused on Alzheimer's treatments, with lead candidate IGC-AD1 in Phase 2 trials targeting agitation in dementia; early results show faster onset than traditional drugs.

• AI-driven MINT-AD platform under development to improve early detection and risk stratification for Alzheimer's, aiming to expand diagnostic access.

• Revenue primarily from white-label and wellness products, with a strategic shift toward pharma-focused programs and clinical development.

• Expanded clinical trial footprint and presented positive safety data for IGC-AD1, supporting regulatory progress.

• Raised $997K through private placements and ATM during the quarter, with additional $2.6M raised post-quarter via ATM.

Financial highlights

• Revenue for Q2 2025 was $328K, up 21% year-over-year; gross margin declined to 47% from 60% due to new product development.

• Net loss for the quarter was $1.6M, a 33% improvement from $2.4M loss in Q2 2024, driven by lower SG&A and higher other income.

• SG&A expenses decreased 28% year-over-year to $1.2M due to cost optimization and headcount alignment.

• R&D expenses were $851K, down 4% year-over-year, with an underlying increase after adjusting for a prior one-time non-cash expense.

• Other income rose to $306K, mainly from a $263K tax credit.

Outlook and guidance

• Current cash, working capital, and a $12M overdraft facility are expected to support operations for at least 12 months.

• Management anticipates increased R&D spending as clinical programs progress, with ongoing efforts to raise additional capital through equity and non-dilutive funding.

• Strategic focus remains on completing Phase 2 IGC-AD1 trials and deploying MINT-AD, with potential divestment or repurposing of non-core assets.